Atrial Fibrillation (AF)AAHINCT07259200
Impact of Atrial Fibrillation Ablation on Sleep Parameters.
An observational study of Atrial Fibrillation (AF) and OSA - Obstructive Sleep Apnea, run by Primula Clinics at 1 site in Poland.
Trial summary
Assessment of Sleep Parameters Using Polygraphy in Patients with Paroxysmal Atrial Fibrillation Qualified for Pulmonary Vein Isolation - A Prospective Observational Study: Afib Ablation and Hypopnea Index - The "AAHI" Study Principal Investigator: Dr. Paweł Basiukiewicz, MD, PhD Study Sponsor: Primula Clinics sp. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation (AF), OSA - Obstructive Sleep Apnea, Pulmonary Vein Isolation
- How many people
- 100 participants
- Where
- 1 sitePoland
- Study dates
- 20 Mar 2025to 28 Feb 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with AFib scheduled for pulmonary vein isolation.
Who may be able to join
- Diagnosis of atrial fibrillation (AFib) and scheduled catheter ablation.
- Presence of at least one OSA risk factor: hypertension, male sex, BMI > 25, diabetes, excessive daytime sleepiness, snoring.
Who cannot join
- Absence of predefined sleep apnea risk factors.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Poland1 site, 1 recruiting
- Recruiting
Primula Clinics
Grodzisk Mazowiecki, 05-825
Paweł Basiukiewicz, MD, PhD, +48 698612826, pbasiukiewicz@gmail.com
About this study
Official title: Assessment of Sleep Parameters Using Polygraphy in Patients With Paroxysmal Atrial Fibrillation Qualified for Pulmonary Vein Isolation - A Prospective Observational Study (AAHI Study)
Assessment of Sleep Parameters Using Polygraphy in Patients with Paroxysmal Atrial Fibrillation Qualified for Pulmonary Vein Isolation - A Prospective Observational Study: Afib Ablation and Hypopnea Index - The "AAHI" Study
Principal Investigator:
Read more
Dr. Paweł Basiukiewicz, MD, PhD
Study Sponsor:
Primula Clinics sp. z o.o. Żyrardowska 31, 05-825 Grodzisk Mazowiecki, Poland NIP (Tax ID): 529 183 03 11
Dear Sir/Madam,
You have been invited to participate in a scientific study aimed at assessing sleep parameters in patients with atrial fibrillation undergoing rhythm-control therapy. Please read this document carefully before deciding whether to take part in the study. If you have any questions, please contact the principal investigator.
Study Objective:
To assess sleep parameters using polygraphy in the course of treatment of patients with paroxysmal atrial fibrillation qualified for pulmonary vein isolation.
Study Procedures:
The study involves four polygraphic sleep studies (two before and two after atrial fibrillation ablation), each conducted at least 7 days apart.
The polygraphic studies will record the following parameters: pulse oximetry, heart rate, respiratory movements of the chest, and airflow through the anterior nares.
The study includes only patients undergoing atrial fibrillation ablation for the first time.
Risks and Benefits:
The study is non-invasive and does not involve any direct health risks. Participation will not affect your treatment process, but it may provide valuable information about your health status.
Voluntary Participation:
Participation in the study is entirely voluntary. You may withdraw from the study at any time without providing a reason and without any impact on your ongoing medical treatment.
Personal Data Protection (GDPR):
In accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (General Data Protection Regulation - GDPR):
The data controller is Primula Clinics sp. z o.o.
Personal data will be processed solely for the purpose of conducting this study.
Data will be stored no longer than required by law or necessary for the research purposes.
You have the right to access your data, request its correction, deletion, restriction of processing, and to object to data processing.
All data will be protected against unauthorized access.
Read the detailed description
Study Title
Assessment of Sleep Parameters Using Polygraphy in Patients With Paroxysmal Atrial Fibrillation Qualified for Pulmonary Vein Isolation - A Prospective Observational Study: AFib Ablation and Hypopnea Index - The "AAHI" Study
Principal Investigator: Dr. Paweł Basiukiewicz, MD, PhD Study Sponsor: Primula Clinics sp. z o.o. Żyrardowska 31, 05-825 Grodzisk Mazowiecki, Poland NIP (Tax ID): 529 183 03 11
- Introduction and Study Rationale
Atrial fibrillation (AFib) is the most common cardiac arrhythmia and is associated with an increased risk of cardiovascular complications and reduced quality of life. Obstructive sleep apnea (OSA) frequently coexists with AFib and may influence both the course of the arrhythmia and the effectiveness of its treatment, including catheter ablation. It is known that atrial fibrillation may exacerbate obstructive sleep apnea through mechanisms such as the loss of atrioventricular synchrony, absence of the so-called "atrial kick," tachycardia, and fluid redistribution within the body during AFib episodes.
The aim of this study is to assess changes in sleep parameters, measured by polygraphy, during the treatment course of patients with atrial fibrillation who are qualified for pulmonary vein isolation.
- Study Objective
To assess sleep parameters using polygraphy during the course of treatment of patients with paroxysmal atrial fibrillation qualified for pulmonary vein isolation.
- Research Hypothesis
Sleep parameters assessed via polygraphy, particularly the Apnea-Hypopnea Index (AHI), change following rhythm-control therapy.
- Study Population
Inclusion Criteria:
Patients with atrial fibrillation who have been previously qualified for AFib ablation.
Presence of at least one risk factor for sleep apnea from the following list: diabetes, hypertension, male sex, BMI > 25, neck circumference > 42 cm in women and > 45 cm in men, upper airway obstruction, history of snoring, daytime sleepiness or fatigue, or witnessed apneic events or choking episodes during sleep.
Exclusion Criteria:
Absence of sleep apnea risk factors.
Lack of consent to participate in the study.
Study Notes:
Polygraphic assessments will be performed as a standard procedure recommended in clinical guidelines, ensuring that the study does not interfere with routine patient care.
Therefore, the study maintains an observational, non-interventional character.
- Study Procedures
- Before the planned AFib ablation: Two polygraphic studies will be performed at least 7 days apart. Recorded channels: pulse oximetry, heart rate, respiratory movements of the chest and abdomen using respiratory inductance plethysmography (RIP) belts, and nasal airflow (pressure) through the anterior nares.
- After AFib ablation: Two polygraphic studies will be performed, at least 7 days apart, beginning one month after the ablation procedure. The same recording channels as above will be used.
- Routine recommendations: All standard-of-care procedures, including lifestyle modification advice and non-pharmacological interventions (e.g., initiation of CPAP therapy, if indicated), will be provided to each patient in accordance with routine clinical practice.
- Ablation procedure:
The ablation is not part of the study. It is a pre-planned, routine clinical procedure scheduled prior to study screening.
- Methodology
Polygraphic Studies:
Certified sleep-monitoring equipment will be used (Nox polygraph, Nox Medical).
Analysis will include AHI, oxygen saturation, heart rate, and respiratory pattern assessment.
Planned Study Population: Approximately 100 participants.
Study Duration: Recruitment period estimated at 6-12 months, with the possibility of extension and inclusion of additional centers if the necessary criteria are met.
Statistical Analysis:
Comparison of pre- and post-ablation sleep parameters using appropriate statistical tests (e.g., paired t-test for parametric data or Wilcoxon test for non-parametric data).
Endpoints: Statistically significant changes in sleep parameters (particularly AHI) recorded by polygraphy.
- Ethics
The study is observational and does not interfere with standard patient treatment.
All participants will provide written informed consent after being informed about the purpose, course, and potential benefits of the study.
The study will be conducted in accordance with the Declaration of Helsinki and approved by the local bioethics committee.
- Results and Application
The study results may provide insight into the potential effects of rhythm-control therapy on sleep parameters in patients with atrial fibrillation. This could contribute to a better understanding of the relationship between these two conditions and to optimizing patient management.
- Keywords
- atrial fibrillation, sleep apnea, sleep apnoea, ablation, pulmonary vein isolation, pvi, snoring, choking, somnolence
- Medical subject headings
- Atrial Fibrillation, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Snoring, Airway Obstruction, Sleepiness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Afib scheduled for PVI, at least one risk factor for obstructive sleep apnea. | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from the baseline in post ablation apnea-hypopnea index (AHI)
Change in apnea - hypopnea index after atrial fibrillation ablation (pulmonary vein isolation). Improvement will be assessed as a decrease in the Apnea-Hypopnea Index.
Measured: From baseline through study completion, an average of 1 year
apnea - hypopnea index (AHI) change
Assessment of change of AHI post PVI procedure.
Measured: From baseline through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2025
- Study start20 Mar 2025
- Primary completion1 Feb 2026 (estimated)
- Study completion28 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Primula Clinics
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paweł S Basiukiewicz, MD, PhD, Principal investigator, Primula Clinics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07259200
- Sponsor's protocol ID
- KB/1641/25
- Acronym
- AAHI
- Status last verified
- Nov 2025
- First submitted
- 13 Nov 2025
- Last updated
- 2 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Database with participants (DOB, HSAT data, PVI date and echocardiograhy findings)
Publications
Shantha G, Pelosi F, Morady F. Relationship Between Obstructive Sleep Apnoea and AF. Arrhythm Electrophysiol Rev. 2019 Jul;8(3):180-183. doi: 10.15420/aer.2019.35.2.
PubMed 31463055Linz D, Baumert M, Desteghe L, Kadhim K, Vernooy K, Kalman JM, Dobrev D, Arzt M, Sastry M, Crijns HJGM, Schotten U, Cowie MR, McEvoy RD, Heidbuchel H, Hendriks J, Sanders P, Lau DH. Nightly sleep apnea severity in patients with atrial fibrillation: Potential applications of long-term sleep apnea monitoring. Int J Cardiol Heart Vasc. 2019 Oct 18;24:100424. doi: 10.1016/j.ijcha.2019.100424. eCollection 2019 Sep.
PubMed 31763438Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available.
PubMed 39210723
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Sleep Parameters Using Polygraphy in Patients With Paroxysmal Atrial Fibrillation Qualified for Pulmonary Vein Isolation - A Prospective Observational Study (AAHI Study)
- ClinicalTrials.gov ID
- NCT07259200
- Acronym / sponsor ID
- AAHI / KB/1641/25
- Keywords
- atrial fibrillation, sleep apnea, sleep apnoea, ablation, pulmonary vein isolation, pvi, snoring, choking
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Primula ClinicsUniversity, hospital or other
- Study start
- 20 Mar 2025 (actual)
- Primary completion
- 1 Feb 2026 (estimated)
- Study completion
- 28 Feb 2026 (estimated)
- First posted
- 2 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assessment of Sleep Parameters Using Polygraphy in Patients with Paroxysmal Atrial Fibrillation Qualified for Pulmonary Vein Isolation - A Prospective Observational Study: Afib Ablation and Hypopnea Index - The "AAHI" Study
Principal Investigator:
Dr. Paweł Basiukiewicz, MD, PhD
Study Sponsor:
Primula Clinics sp. z o.o. Żyrardowska 31, 05-825 Grodzisk Mazowiecki, Poland NIP (Tax ID): 529 183 03 11
Dear Sir/Madam,
You have been invited to participate in a scientific study aimed at assessing sleep parameters in patients with atrial fibrillation undergoing rhythm-control therapy. Please read this document carefully before deciding whether to take part in the study. If you have any questions, please contact the principal investigator.
Study Objective:
To assess sleep parameters using polygraphy in the course of treatment of patients with paroxysmal atrial fibrillation qualified for pulmonary vein isolation.
Study Procedures:
The study involves four polygraphic sleep studies (two before and two after atrial fibrillation ablation), each conducted at least 7 days apart.
The polygraphic studies will record the following parameters: pulse oximetry, heart rate, respiratory movements of the chest, and airflow through the anterior nares.
The study includes only patients undergoing atrial fibrillation ablation for the first time.
Risks and Benefits:
The study is non-invasive and does not involve any direct health risks. Participation will not affect your treatment process, but it may provide valuable information about your health status.
Voluntary Participation:
Participation in the study is entirely voluntary. You may withdraw from the study at any time without providing a reason and without any impact on your ongoing medical treatment.
Personal Data Protection (GDPR):
In accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (General Data Protection Regulation - GDPR):
The data controller is Primula Clinics sp. z o.o.
Personal data will be processed solely for the purpose of conducting this study.
Data will be stored no longer than required by law or necessary for the research purposes.
You have the right to access your data, request its correction, deletion, restriction of processing, and to object to data processing.
All data will be protected against unauthorized access.
Detailed description
Study Title
Assessment of Sleep Parameters Using Polygraphy in Patients With Paroxysmal Atrial Fibrillation Qualified for Pulmonary Vein Isolation - A Prospective Observational Study: AFib Ablation and Hypopnea Index - The "AAHI" Study
Principal Investigator: Dr. Paweł Basiukiewicz, MD, PhD Study Sponsor: Primula Clinics sp. z o.o. Żyrardowska 31, 05-825 Grodzisk Mazowiecki, Poland NIP (Tax ID): 529 183 03 11
- Introduction and Study Rationale
Atrial fibrillation (AFib) is the most common cardiac arrhythmia and is associated with an increased risk of cardiovascular complications and reduced quality of life. Obstructive sleep apnea (OSA) frequently coexists with AFib and may influence both the course of the arrhythmia and the effectiveness of its treatment, including catheter ablation. It is known that atrial fibrillation may exacerbate obstructive sleep apnea through mechanisms such as the loss of atrioventricular synchrony, absence of the so-called "atrial kick," tachycardia, and fluid redistribution within the body during AFib episodes.
The aim of this study is to assess changes in sleep parameters, measured by polygraphy, during the treatment course of patients with atrial fibrillation who are qualified for pulmonary vein isolation.
- Study Objective
To assess sleep parameters using polygraphy during the course of treatment of patients with paroxysmal atrial fibrillation qualified for pulmonary vein isolation.
- Research Hypothesis
Sleep parameters assessed via polygraphy, particularly the Apnea-Hypopnea Index (AHI), change following rhythm-control therapy.
- Study Population
Inclusion Criteria:
Patients with atrial fibrillation who have been previously qualified for AFib ablation.
Presence of at least one risk factor for sleep apnea from the following list: diabetes, hypertension, male sex, BMI > 25, neck circumference > 42 cm in women and > 45 cm in men, upper airway obstruction, history of snoring, daytime sleepiness or fatigue, or witnessed apneic events or choking episodes during sleep.
Exclusion Criteria:
Absence of sleep apnea risk factors.
Lack of consent to participate in the study.
Study Notes:
Polygraphic assessments will be performed as a standard procedure recommended in clinical guidelines, ensuring that the study does not interfere with routine patient care.
Therefore, the study maintains an observational, non-interventional character.
- Study Procedures
- Before the planned AFib ablation: Two polygraphic studies will be performed at least 7 days apart. Recorded channels: pulse oximetry, heart rate, respiratory movements of the chest and abdomen using respiratory inductance plethysmography (RIP) belts, and nasal airflow (pressure) through the anterior nares.
- After AFib ablation: Two polygraphic studies will be performed, at least 7 days apart, beginning one month after the ablation procedure. The same recording channels as above will be used.
- Routine recommendations: All standard-of-care procedures, including lifestyle modification advice and non-pharmacological interventions (e.g., initiation of CPAP therapy, if indicated), will be provided to each patient in accordance with routine clinical practice.
- Ablation procedure:
The ablation is not part of the study. It is a pre-planned, routine clinical procedure scheduled prior to study screening.
- Methodology
Polygraphic Studies:
Certified sleep-monitoring equipment will be used (Nox polygraph, Nox Medical).
Analysis will include AHI, oxygen saturation, heart rate, and respiratory pattern assessment.
Planned Study Population: Approximately 100 participants.
Study Duration: Recruitment period estimated at 6-12 months, with the possibility of extension and inclusion of additional centers if the necessary criteria are met.
Statistical Analysis:
Comparison of pre- and post-ablation sleep parameters using appropriate statistical tests (e.g., paired t-test for parametric data or Wilcoxon test for non-parametric data).
Endpoints: Statistically significant changes in sleep parameters (particularly AHI) recorded by polygraphy.
- Ethics
The study is observational and does not interfere with standard patient treatment.
All participants will provide written informed consent after being informed about the purpose, course, and potential benefits of the study.
The study will be conducted in accordance with the Declaration of Helsinki and approved by the local bioethics committee.
- Results and Application
The study results may provide insight into the potential effects of rhythm-control therapy on sleep parameters in patients with atrial fibrillation. This could contribute to a better understanding of the relationship between these two conditions and to optimizing patient management.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Afib scheduled for PVI, at least one risk factor for obstructive sleep apnea. | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with AFib scheduled for pulmonary vein isolation.
Key inclusion criteria (2 listed)
- Diagnosis of atrial fibrillation (AFib) and scheduled catheter ablation.
- Presence of at least one OSA risk factor: hypertension, male sex, BMI > 25, diabetes, excessive daytime sleepiness, snoring.
Key exclusion criteria (1 listed)
- Absence of predefined sleep apnea risk factors.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change from the baseline in post ablation apnea-hypopnea index (AHI)
Time frame: From baseline through study completion, an average of 1 year
Change in apnea - hypopnea index after atrial fibrillation ablation (pulmonary vein isolation). Improvement will be assessed as a decrease in the Apnea-Hypopnea Index.
apnea - hypopnea index (AHI) change
Time frame: From baseline through study completion, an average of 1 year
Assessment of change of AHI post PVI procedure.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2025.
- Background: PubMed 31463055Shantha G, Pelosi F, Morady F. Relationship Between Obstructive Sleep Apnoea and AF. Arrhythm Electrophysiol Rev. 2019 Jul;8(3):180-183. doi: 10.15420/aer.2019.35.2.
- Background: PubMed 31763438Linz D, Baumert M, Desteghe L, Kadhim K, Vernooy K, Kalman JM, Dobrev D, Arzt M, Sastry M, Crijns HJGM, Schotten U, Cowie MR, McEvoy RD, Heidbuchel H, Hendriks J, Sanders P, Lau DH. Nightly sleep apnea severity in patients with atrial fibrillation: Potential applications of long-term sleep apnea monitoring. Int J Cardiol Heart Vasc. 2019 Oct 18;24:100424. doi: 10.1016/j.ijcha.2019.100424. eCollection 2019 Sep.
- Background: PubMed 39210723Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available.
- Individual participant dataSharing planned: Yes. Database with participants (DOB, HSAT data, PVI date and echocardiograhy findings)
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Paweł S Basiukiewicz, MD, PhD principal investigator
Primula Clinics
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation (AF) and OSA - Obstructive Sleep Apnea, run by Primula Clinics at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Paweł S Basiukiewicz, MD, PhD (+48 698612826, pbasiukiewicz@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from the baseline in post ablation apnea-hypopnea index (AHI) (time frame: From baseline through study completion, an average of 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07259200, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.